Affimed (NASDAQ: AFMD)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Affimed Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Affimed Company Info
Affimed Therapeutics B.V.
News & Analysis
The clinical-stage biotech focuses on immuno-oncology therapies.
An analyst's downgrade brings out the bears for the European cancer treatment developer.
This billionaire-guided hedge fund went bargain-shopping in the second quarter.
The biotech's experimental blood cancer treatment could be a major advancement.
Finding stocks with significant upside before the rest of the market sees what's happening can be highly profitable.
Affimed, Amgen, and Bristol Myers Squibb are too cheap to ignore right now.
The biotech's early-stage trial results are turning heads on Wall Street today.
Positive trial results regarding the company's pipeline are buoying the stock's price.
AFMD earnings call for the period ending September 30, 2021.
AFMD earnings call for the period ending June 30, 2021.
AFMD earnings call for the period ending September 30, 2020.
AFMD earnings call for the period ending June 30, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.